Cellectis Ret. on equity
What is the Ret. on equity of Cellectis?
The Ret. on equity of Cellectis is -50.68%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with ret. on equity similar to Cellectis
- Verisign has Ret. on equity of -50.77%
- Visionary Gold has Ret. on equity of -50.74%
- Exore Resources has Ret. on equity of -50.73%
- TSS has Ret. on equity of -50.72%
- Cymabay Therapeutics Inc has Ret. on equity of -50.72%
- Locksley Resources Ltd has Ret. on equity of -50.70%
- Cellectis has Ret. on equity of -50.68%
- Liberty One Lithium has Ret. on equity of -50.63%
- Advenis SA has Ret. on equity of -50.59%
- Harrow Health has Ret. on equity of -50.56%
- Goldsource Mines has Ret. on equity of -50.55%
- Home Point Capital has Ret. on equity of -50.55%
- Haidilao International has Ret. on equity of -50.52%